Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:JAGX
- CUSIP: N/A
- Web: www.jaguaranimalhealth.com
Capitalization:- Market Cap: $44.23 million
- Outstanding Shares: 108,202,000
Average Prices:- 50 Day Moving Avg: $0.44
- 200 Day Moving Avg: $0.44
- 52 Week Range: $0.36 - $1.53
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.86
- P/E Growth: -0.0100
Sales & Book Value:- Annual Revenue: $1.79 million
- Price / Sales: 24.71
- Book Value: ($0.62) per share
- Price / Book: -0.66
Profitability:- Net Margins: -757.17%
- Return on Equity: -1,693.45%
- Return on Assets: -301.91%
Debt:- Debt-to-Equity Ratio: -0.13%
- Current Ratio: 0.38%
- Quick Ratio: 0.34%
Misc:- Average Volume: 436,600 shs.
- Beta: 0.67
- Short Ratio: 2
Frequently Asked Questions for Jaguar Animal Health (NASDAQ:JAGX)
What is Jaguar Animal Health's stock symbol?
Jaguar Animal Health trades on the NASDAQ under the ticker symbol "JAGX."
How were Jaguar Animal Health's earnings last quarter?
Jaguar Animal Health, Inc. (NASDAQ:JAGX) announced its quarterly earnings data on Monday, November, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.10. The firm had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.10 million. Jaguar Animal Health had a negative net margin of 757.17% and a negative return on equity of 1,693.45%. View Jaguar Animal Health's Earnings History.
Where is Jaguar Animal Health's stock going? Where will Jaguar Animal Health's stock price be in 2017?
2 analysts have issued 12-month price targets for Jaguar Animal Health's shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Jaguar Animal Health's stock price to reach $2.00 in the next twelve months. View Analyst Ratings for Jaguar Animal Health.
Are investors shorting Jaguar Animal Health?
Jaguar Animal Health saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 2,176,922 shares, an increase of 46.6% from the July 31st total of 1,484,579 shares. Based on an average trading volume of 474,227 shares, the short-interest ratio is currently 4.6 days.
Who are some of Jaguar Animal Health's key competitors?
Some companies that are related to Jaguar Animal Health include Eiger BioPharmaceuticals (EIGR), Zynerba Pharmaceuticals (ZYNE), ArQule (ARQL), Vernalis plc (VER), Brainstorm Cell Therapeutics (BCLI), CytRx Corporation (CYTR), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Galectin Therapeutics (GALT), Navidea Biopharmaceuticals (NAVB), Infinity Pharmaceuticals (INFI), ReNeuron Group Plc (RENE), OvaScience (OVAS), Fibrocell Science (FCSC), Abzena PLC (ABZA), Sunesis Pharmaceuticals (SNSS), Bio-Path Holdings (BPTH) and Aptose Biosciences (APTO).
Who are Jaguar Animal Health's key executives?
Jaguar Animal Health's management team includes the folowing people:
- James J. Bochnowski, Chairman of the Board
- Lisa A. Conte, President, Chief Executive Officer, Director
- Karen Wright, Chief Financial Officer
- John A. Kallassy, Chief Operating Officer, Executive Vice President, Treasurer
- Steven R. King Ph.D., Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary
- Ari Azhir PhD, Director
- Folkert W Kamphuis, Director
- John J. Micek III J.D., Director
- Jiahao Qiu, Director
- Zhi Yang Ph.D., Director
When did Jaguar Animal Health IPO?
(JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
Who owns Jaguar Animal Health stock?
How do I buy Jaguar Animal Health stock?
Shares of Jaguar Animal Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jaguar Animal Health's stock price today?
One share of Jaguar Animal Health stock can currently be purchased for approximately $0.41.
MarketBeat Community Rating for Jaguar Animal Health (NASDAQ JAGX)MarketBeat's community ratings are surveys of what our community members think about Jaguar Animal Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Jaguar Animal Health (NASDAQ:JAGX)Earnings History by Quarter for Jaguar Animal Health (NASDAQ JAGX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2016 | 9/30/2016 | ($0.40) | ($0.30) | $0.10 million | $0.05 million | View | N/A |  |
(Data available from 1/1/2011 forward)
Earnings Estimates for Jaguar Animal Health (NASDAQ:JAGX)2017 EPS Consensus Estimate: ($1.09)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.21) | ($0.21) | ($0.21) |
| Q2 2017 | 1 | ($0.28) | ($0.28) | ($0.28) |
| Q3 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
| Q4 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
(Data provided by Zacks Investment Research)
Dividend History for Jaguar Animal Health (NASDAQ:JAGX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Jaguar Animal Health (NASDAQ:JAGX)Insider Ownership Percentage: 19.50%
Institutional Ownership Percentage: 26.59%
Insider Trades by Quarter for Jaguar Animal Health (NASDAQ:JAGX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/8/2016 | James J Bochnowski | Director | Buy | 160,000 | $2.50 | $400,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Jaguar Animal Health (NASDAQ:JAGX)
Latest Headlines for Jaguar Animal Health (NASDAQ:JAGX)
| Source: |
|
| Date | Headline |
|---|
 | FDA Indicates That Jaguar’s Canalevia Drug Product Candidate Qualifies as “Minor Use” for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for ...
www.businesswire.com - September 20 at 4:34 PM |
 | FDA Indicates That Jaguar’s Canalevia Drug Product Candidate Qualifies as “Minor Use” for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication
finance.yahoo.com - September 20 at 4:34 PM |
| Jaguar Health Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 18 at 7:35 PM |
| Advocates Tez Anderson and Josh Robbins to Host Facebook Live Conversation on HIV/AIDS and Aging Awareness Day to Discuss Issues Affecting Long Term Survivors
finance.yahoo.com - September 18 at 7:35 PM |
| Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets
finance.yahoo.com - September 16 at 2:31 AM |
| New Survey Ranks Diarrhea as Number One Gastrointestinal Complaint of HIV/AIDS Patients
finance.yahoo.com - September 12 at 4:55 PM |
 | Jaguar Animal Health, Inc. (JAGX) Short Interest Up 46.6% in August
www.americanbankingnews.com - August 28 at 1:20 AM |
| Jaguar Health, Inc. :JAGX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 6:24 AM |
| Jaguar Health Company Name Now Updated on Nasdaq.com Post-Merger
finance.yahoo.com - August 16 at 7:59 PM |
| Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation for Mytesi (crofelemer) for Treatment of Short Bowel Syndrome
finance.yahoo.com - August 7 at 7:27 PM |
| Bio-Techne Corp (TECH) versus Jaguar Animal Health (NASDAQ:JAGX) Head-To-Head Contrast
www.americanbankingnews.com - August 1 at 6:32 PM |
| The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective
finance.yahoo.com - August 1 at 12:27 AM |
| Jaguar Animal Health, Inc. (NASDAQ:JAGX) Sees Large Growth in Short Interest
www.americanbankingnews.com - July 29 at 7:11 AM |
| Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger
finance.yahoo.com - July 27 at 11:35 PM |
 | Napo Pharma announces positive data on HIV diarrheal product Mytesi; merger partner Jaguar Animal Health up 2%
seekingalpha.com - July 25 at 5:37 AM |
| New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment
finance.yahoo.com - July 25 at 12:35 AM |
| Jaguar Neonorm Foal Study Accepted for Publication in Veterinary Journal
finance.yahoo.com - July 18 at 4:58 PM |
| Jaguar Animal Health, Inc. (JAGX) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - July 11 at 7:52 AM |
| Rodman & Renshaw Begins Coverage on Jaguar Animal Health, Inc. (JAGX)
www.americanbankingnews.com - July 11 at 7:52 AM |
| Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to Vote Upon the Consummation of its Proposed Merger with Napo Pharmaceuticals, Inc.
finance.yahoo.com - July 7 at 6:36 AM |
| SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Jaguar Animal Health, Inc. - JAGX
finance.yahoo.com - June 30 at 8:14 PM |
| Napo Pharmaceuticals to Present New Crofelemer (Mytesi) Data at International Aids Society Conference on HIV Science
finance.yahoo.com - June 27 at 6:12 PM |
 | BRIEF-Jaguar Animal says OMRI has reviewed Neonorm Calf
www.reuters.com - June 14 at 8:02 PM |
| Jaguar Animal Health’s Neonorm Calf Obtains OMRI Listing and Can Now be Used in Production of Certified Organic Dairy and Beef Cattle
finance.yahoo.com - June 14 at 10:33 AM |
| Short Interest in Jaguar Animal Health Inc (JAGX) Drops By 1.7%
www.americanbankingnews.com - June 7 at 7:22 PM |
| Jaguar Animal Health Launches Commercial Website for Neonorm Foal & Neonorm Calf
finance.yahoo.com - June 7 at 9:56 AM |
| Jaguar Animal Health and Napo Pharmaceuticals Announce Filing of Two Orphan Drug Designation Applications with FDA for Mytesi for Serious Unmet Medical Needs
finance.yahoo.com - June 5 at 10:08 AM |
| Jaguar Animal Health, Inc. :JAGX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 7:27 PM |
| Lisa Conte, CEO of Jaguar Animal Health and Napo Pharmaceuticals, to Present at the Southern California Investment Forum May 31, 2017 in Los Angeles
finance.yahoo.com - May 26 at 2:38 AM |
| Napo Pharmaceuticals’ New Mytesi Video Calls Attention to the Continuing Widespread Problem of Diarrhea in People Living With HIV/AIDS
finance.yahoo.com - May 24 at 11:24 AM |
| Jaguar Animal Health (JAGX)
seekingalpha.com - May 19 at 5:44 PM |
| Jaguar Animal Health and Napo Pharmaceuticals Appoint Dr. Pravin Chaturvedi to Chair Scientific Advisory Board
finance.yahoo.com - May 10 at 1:13 PM |
 | Jaguar Animal Health (JAGX) Signs Distribution Agreement for Neonorm Foal and Neonorm Calf in Japan
www.streetinsider.com - April 29 at 11:34 PM |
| Jaguar Animal Health (JAGX) Receives Daily News Sentiment Rating of 0.19
www.americanbankingnews.com - April 29 at 7:44 PM |
| BRIEF-Jaguar signs distribution agreement JP Equine Services
www.reuters.com - April 28 at 9:47 AM |
| Jaguar Signs Distribution Agreement for Japan for Neonorm Foal & Neonorm Calf
finance.yahoo.com - April 28 at 9:47 AM |
| Jaguar Animal Health (JAGX) Given Media Impact Rating of 0.19
www.americanbankingnews.com - April 21 at 4:19 PM |
| Jaguar Animal Health set to launch ad campaigns to support Neonorm; shares ahead 5% premarket
seekingalpha.com - April 7 at 10:32 AM |
| Jaguar and Napo Issue Commercial Updates
finance.yahoo.com - April 7 at 10:32 AM |
| Jaguar Animal Health (JAGX) Enters Merger Agreement with Napo Pharmaceuticals - StreetInsider.com
www.streetinsider.com - April 2 at 10:02 AM |
| Jaguar Animal Health (JAGX) Enters Merger Agreement with Napo Pharmaceuticals - StreetInsider.com
www.streetinsider.com - April 2 at 10:02 AM |
| Jaguar Animal Health (JAGX) Enters Merger Agreement with Napo Pharmaceuticals
www.streetinsider.com - March 31 at 6:03 PM |
 | Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger Agreement
us.rd.yahoo.com - March 31 at 6:03 PM |
 | Jaguar Animal Health Stock Skyrocketing on Napo Pharma Merger
www.thestreet.com - March 31 at 6:03 PM |
| Jaguar Animal Health Stock Rises on Napo Pharma Merger
www.thestreet.com - March 31 at 6:03 PM |
| After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite
www.thestreet.com - March 31 at 6:03 PM |
| Jaguar Animal Health (JAGX) Enters Exclusive Evaluation Period With Multinational Animal Health Pharmaceutical ... - StreetInsider.com
www.streetinsider.com - March 30 at 8:08 AM |
| Jaguar Animal Health Inc (JAGX) Receives Consensus Recommendation of "" from Brokerages
www.americanbankingnews.com - March 29 at 12:19 PM |
| BRIEF-Jaguar Animal health-entered exclusive 60-day evaluation period
www.reuters.com - March 28 at 11:04 AM |
| Jaguar Animal Health (JAGX) Enters Exclusive Evaluation Period With Multinational Animal Health Pharmaceutical Firm Regarding Equilevia
www.streetinsider.com - March 28 at 11:04 AM |
Jaguar Animal Health (JAGX) Chart for Sunday, September, 24, 2017
